Literature DB >> 2957444

Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice.

B E Johansson, T M Moran, C A Bona, E D Kilbourne.   

Abstract

In BALB/c mice primed by influenza virus infection to H3 hemagglutinin and N2 neuraminidase, presentation of N2 in association with a heterosubtypic (H7) hemagglutinin results in production of a greater amount of N2 antibody than is found with homologous (H3N2) reimmunization. Titration of primed helper T cell (Th) activity by adoptive transfer of purified T cells to athymic mice given H6N2 vaccine demonstrates a lesser number of N2-specific Th cells in mice subjected to homologous reimmunization. We conclude that Th cells participate in the mediation of intermolecular (intravirionic) antigenic competition between influenza virus hemagglutinin and neuraminidase.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957444

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice.

Authors:  Judith D Easterbrook; Louis M Schwartzman; Jin Gao; John C Kash; David M Morens; Laura Couzens; Hongquan Wan; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Virology       Date:  2012-06-22       Impact factor: 3.616

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.

Authors:  B E Johansson; D J Bucher; E D Kilbourne
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition.

Authors:  B E Johansson; E D Kilbourne
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.

Authors:  P A Scherle; W Gerhard
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Authors:  Chia-Ying Wu; Yi-Chun Yeh; Jia-Tsrong Chan; Yu-Chih Yang; Ji-Rong Yang; Ming-Tsan Liu; Ho-Sheng Wu; Pei-Wen Hsiao
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

9.  A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.

Authors:  Glendie Marcelin; Rebecca DuBois; Adam Rubrum; Charles J Russell; Janet E McElhaney; Richard J Webby
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

10.  The evolution of humoral immune responses to past and novel influenza virus strains gives evidence for antigenic seniority.

Authors:  Federica Sicca; Eleni Sakorafa; Anouk de Jonge; Jacqueline de Vries-Idema; Fan Zhou; Rebecca Jane Cox; Anke Huckriede
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.